Annual report pursuant to Section 13 and 15(d)

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

12 Months Ended

Dec. 31, 2023

ROYALTY OBLIGATIONS NET

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(7,384	)		$	(5,113	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(1,787	)		$	(1,790	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(18,782	)		$	(8,211	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(4,545	)		$	(2,874	)

Schedule of changes in non-controlling interest

Balance, December 31, 2022		$	(125,257	)
Net loss attributable to the non-controlling interest			(3,577	)
Balance, December 31, 2023			(128,834	)

Balance, December 31, 2021		$	(117,838	)
Net loss attributable to the non-controlling interest			(7,419	)
Balance, December 31, 2022			(125,257	)